Targeting E3 ubiquitin ligases for cancer therapy

Cancer Biology and Therapy

Volumn 2, Issue 6, 2003, Pages 623-629

  Sun, Yi ^a  

^a NONE

Author keywords

Apoptosis; Cancer targets; Drug discovery; E3 ubiquitin ligases; High throughput screening; Protein degradation

Indexed keywords

ANTINEOPLASTIC AGENT; CYSTEINE PROTEINASE; ENZYME INHIBITOR; LIGASE; MULTIENZYME COMPLEX; PROTEASOME; UBIQUITIN;

ANIMAL; APOPTOSIS; BIOLOGICAL MODEL; CATALYSIS; CHEMISTRY; CLASSIFICATION; DRUG ANTAGONISM; DRUG EFFECT; ENZYME SPECIFICITY; ENZYMOLOGY; FORECASTING; GENETICS; HUMAN; METABOLISM; NEOPLASM; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CATALYSIS; CYSTEINE ENDOPEPTIDASES; ENZYME INHIBITORS; FORECASTING; HUMANS; LIGASES; MODELS, BIOLOGICAL; MULTIENZYME COMPLEXES; NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN STRUCTURE, TERTIARY; SUBSTRATE SPECIFICITY; UBIQUITIN;

EID: 2642559887     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.2.6.677     Document Type: Review

References (106)

1. Ciechanover A. The ubiquitin-proteasome pathway: On protein death and cell life. EMBO J 1998; 17:7151-60. (Pubitemid 29002684)
2. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998; 67:425-79.
3. Varshavsky A. The N-end rule and regulation of apoptosis. Nat Cell Biol 2003; 5:373-6.
4. Varshavsky A. The N-end rule pathway of protein degradation. Genes Cells 1997; 2:13-28. (Pubitemid 127688555)
5. Ditzel M, Wilson R, Tenev T, Zachariou A, Paul A, Deas E, et al. Degradation of DIAP1 by the N-end rule pathway is essential for regulating apoptosis. Nat Cell Biol 2003; 5:467-73. (Pubitemid 36592271)
6. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993; 75:495-505. (Pubitemid 23335075)
7. Scheffner M, Nuber U, Huibregtse JM. Protein ubiquitination involving an E1-E2-E3 enzyme ubiquitin thioester cascade. Nature 1995; 373:81-3.
8. Schwarz SE, Rosa JL, Scheffner M. Characterization of human hect domain family members and their interaction with UbcH5 and UbcH7. J Biol Chem 1998; 273:12148-54. (Pubitemid 28240577)
9. Freemont PS. RING for destruction? Curr Biol 2000; 10:R84-7.
10. Saurin AJ, Borden KL, Boddy MN, Freemont PS. Does this have a familiar RING? Trends Biochem Sci 1996; 21:208-14.
11. Lorick KL, Jensen JP, Fang S, Ong AM, Hatakeyama S, Weissman AM. RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination. Proc Natl Acad Sci USA 1999; 96:11364-9.
12. Fang S, Jensen JP, Ludwig RL, Vousden KH, Weissman AM. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem 2000; 275:8945-51. (Pubitemid 30180252)
13. Joazeiro CA, Weissman AM. RING finger proteins: Mediators of ubiquitin ligase activity. Cell 2000; 102:549-52.
14. Fang S, Lorick KL, Jensen JP, Weissman AM. RING finger ubiquitin protein ligases: Implications for tumorigenesis, metastasis and for molecular targets in cancer. Semin Cancer Biol 2003; 13:5-14. (Pubitemid 36269176)
15. Aravind L, Koonin EV. The U box is a modified RING finger - a common domain in ubiquitination. Curr Biol 2000; 10:R132-4.
16. Jiang J, Ballinger CA, Wu Y, Dai Q, Cyr DM, Hohfeld J, et al. CHIP is a U-box-dependent E3 ubiquitin ligase: Identification of Hsc70 as a target for ubiquitylation. J Biol Chem 2001; 276:42938-44.
17. Hatakeyama S, Yada M, Matsumoto M, Ishida N, Nakayama KI. U box proteins as a new family of ubiquitin-protein ligases. J Biol Chem 2001; 276:33111-20.
18. Lu Z, Xu S, Joazeiro C, Cobb MH, Hunter T. The PHD domain of MEKK1 acts as an E3 ubiquitin ligase and mediates ubiquitination and degradation of ERK1/2. Mol Cell 2002; 9:945-56. (Pubitemid 34626666)
19. Coscoy L, Ganem D. PHD domains and E3 ubiquitin ligases: Viruses make the connection. Trends Cell Biol 2003; 13:7-12. (Pubitemid 35453890)
20. Cahilly-Snyder L, Yang-Feng T, Francke U, George DL. Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somat Cell Mol Genet 1987; 13:235-44.
21. Freedman DA, Wu L, Levine AJ. Functions of the MDM2 oncoprotein. Cell Mol Life Sci 1999; 55:96-107.
22. Zhang, Wang H. MDM2 oncogene as a novel target for human cancer therapy. Curr Pharm Des 2000; 6:393-416.
23. Momand J, Jung D, Wilczynski S, Niland J. The MDM2 gene amplification database. Nucleic Acids Res 1998; 26:3453-9.
24. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54:4855-78. (Pubitemid 24289415)
25. Giaccia AJ, Kastan MB. The complexity of p53 modulation: Emerging patterns from divergent signals. Genes Dev 1998; 12:2973-83. (Pubitemid 28469299)
26. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408:307-10.
27. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387:296-9. (Pubitemid 27220766)
28. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997; 387:299-303.
29. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 1997; 420:25-7. (Pubitemid 28037193)
30. Honda R, Yasuda H. Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase. Oncogene 2000; 19:1473-6. (Pubitemid 30171179)
31. Montes de Oca Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 1995; 378:203-6.
32. de Rozieres S, Maya R, Oren M, Lozano G. The loss of mdm2 induces p53-mediated apoptosis. Oncogene 2000; 19:1691-7. (Pubitemid 30200971)
33. Ries S, Biederer C, Woods D, Shifman O, Shirasawa S, Sasazuki T, et al. Opposing effects of Ras on p53: Transcriptional activation of mdm2 and induction of p19ARF. Cell 2000; 103:321-30.
34. Freedman DA, Levine AJ. Regulation of the p53 protein by the MDM2 oncoprotein - thirty-eighth G.H.A. Clowes Memorial Award Lecture. Cancer Res 1999; 59:1-7. (Pubitemid 29062945)
35. Wasylyk C, Salvi R, Argentini M, Dureuil C, Delumeau I, Abecassis J, et al. p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53. Oncogene 1999; 18:1921-34. (Pubitemid 29150079)
36. Duncan SJ, Cooper MA, Williams DH. Binding of an inhibitor of the p53/MDM2 interaction to MDM2. Chem Commun (Camb) 2003: 316-7. (Pubitemid 36207694)
37. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998; 92:725-34. (Pubitemid 28155312)
38. Midgley CA, Desterro JM, Saville MK, Howard S, Sparks A, Hay RT, et al. An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo. Oncogene 2000; 19:2312-23. (Pubitemid 30307207)
39. Wang H, Nan L, Yu D, Lindsey JR, Agrawal S, Zhang R. Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53- independent mechanisms. Mol Med 2002; 8:185-99. (Pubitemid 35013750)
40. Wang H, Yu D, Agrawal S, Zhang R. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: In vitro and in vivo activities and mechanisms. Prostate 2003; 54:194-205. (Pubitemid 36120317)
41. Hietanen S, Lain S, Krausz E, Blattner C, Lane DP. Activation of p53 in cervical carcinoma cells by small molecules. Proc Natl Acad Sci USA 2000; 97:8501-6. (Pubitemid 30639702)
42. Lai Z, Yang T, Kim YB, Sielecki TM, Diamond MA, Strack P, et al. Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors. Proc Natl Acad Sci USA 2002; 99:14734-9. (Pubitemid 35334553)
43. Jones SN, Hancock AR, Vogel H, Donehower LA, Bradley A. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci USA 1998; 95:15608-12. (Pubitemid 29018747)
44. Xiao ZX, Chen J, Levine AJ, Modjtahedi N, Xing J, Sellers WR, et al. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 1995; 375:694-8.
45. Lohrum MA, Ashcroft M, Kubbutat MH, Vousden KH. Identification of a cryptic nucleolar- localization signal in MDM2. Nat Cell Biol 2000; 2:179-81.
46. Grossman SR, Perez M, Kung AL, Joseph M, Mansur C, Xiao ZX, et al. p300/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol Cell 1998; 2:405-15. (Pubitemid 128381293)
47. Swaroop M, Sun Y. Mdm2 ligase dead mutants did not act in a dominant negative manner to reactivate p53, but promoted tumor cell growth. Anticancer Res 2003; 23:3167-74. (Pubitemid 36975410)
48. Deveraux QL, Reed JC. IAP family proteins - suppressors of apoptosis. Genes Dev 1999; 13:239-52. (Pubitemid 29095796)
49. Yang YL, Li XM. The IAP family: Endogenous caspase inhibitors with multiple biological activities. Cell Res 2000; 10:169-77.
50. Salvesen GS, Duckett CS. IAP proteins: Blocking the road to death's door. Nat Rev Mol Cell Biol 2002; 3:401-10. (Pubitemid 34685698)
51. Ashhab Y, Alian A, Polliack A, Panet A, Yehuda DB. Two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pattern. FEBS Lett 2001; 495:56-60. (Pubitemid 32367973)
52. Vucic D, Stennicke HR, Pisabarro MT, Salvesen GS, Dixit VM. ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr Biol 2000; 10:1359-66.
53. Shi Y. Mechanisms of caspase activation and inhibition during apoptosis. Mol Cell 2002; 9:459-70. (Pubitemid 34273778)
54. Suzuki Y, Nakabayashi Y, Nakata K, Reed JC, Takahashi R. X-linked inhibitor of apoptosis protein (XIAP) inhibits caspase-3 and - 7 in distinct modes. J Biol Chem 2001; 276:27058-63.
55. Suzuki Y, Nakabayashi Y, Takahashi R. Ubiquitin-protein ligase activity of X-linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its anti-apoptotic effect in Fas-induced cell death. Proc Natl Acad Sci USA 2001; 98:8662-7. (Pubitemid 32678084)
56. Huang H, Joazeiro CA, Bonfoco E, Kamada S, Leverson JD, Hunter T. The inhibitor of apoptosis, cIAP2, functions as a ubiquitin-protein ligase and promotes in vitro monoubiquitination of caspases 3 and 7. J Biol Chem 2000; 275:26661-4.
57. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003; 3:46-54. (Pubitemid 37328886)
58. Holcik M, Gibson H, Korneluk RG. XIAP: Apoptotic brake and promising therapeutic target. Apoptosis 2001; 6:253-61. (Pubitemid 32708519)
59. Imoto I, Tsuda H, Hirasawa A, Miura M, Sakamoto M, Hirohashi S, et al. Expression of cIAP1, a target for 11q22 amplification, correlates with resistance of cervical cancers to radiotherapy. Cancer Res 2002; 2:4860-6. (Pubitemid 34984404)
60. Wu G, Chai J, Suber TL, Wu JW, Du C, Wang X, Shi Y. Structural basis of IAP recognition by Smac/DIABLO. Nature 2000; 08:1008-12. (Pubitemid 32101651)
61. Chai J, Du C, Wu JW, Kyin S, Wang X, Shi Y. Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature 2000; 06:855-62. (Pubitemid 30664254)
62. Hu S, Yang X. Cellular Inhibitor of Apoptosis 1 and 2 Are Ubiquitin Ligases for the Apoptosis Inducer Smac/DIABLO. J Biol Chem 2003; 78:10055-60. (Pubitemid 36800260)
63. MacFarlane M, Merrison W, Bratton SB, Cohen GM. Proteasome-mediated degradation of Smac during apoptosis: XIAP promotes Smac ubiquitination in vitro. J Biol Chem 2002; 77:36611-6.
64. Yang Y, Fang S, Jensen JP, Weissman AM, Ashwell JD. Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science 2000; 88:874-7. (Pubitemid 30257739)
65. Li J, Feng Q, Kim JM, Schneiderman D, Liston P, Li M, et al. Human ovarian cancer and cisplatin resistance: Pssible role of inhibitor of apoptosis proteins. Endocrinology 2001; 42:370-80. (Pubitemid 32183698)
66. Sasaki H, Sheng Y, Kotsuji F, Tsang BK. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res 2000; 0:5659-66.
67. Chen J, Wu W, Tahir SK, Kroeger PE, Rosenberg SH, Cowsert LM, et al. Down-regulation of survivin by antisense oligonucleotides increases apoptosis, inhibits cytokinesis and anchorage-independent growth. Neoplasia 2000; :235-41. (Pubitemid 30346079)
68. Olie RA, Simoes-Wust AP, Baumann B, Leech SH, Fabbro D, Stahel RA, et al. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 2000; 60:2805-9. (Pubitemid 30395796)
69. Hu Y, Cherton-Horvat G, Dragowska V, Baird S, Korneluk RG, Durkin JP, et al. ntisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clin Cancer Res 2003; 9:2826-36. (Pubitemid 36842129)
70. Fulda S, Wick W, Weller M, Debatin KM. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 2002; 8:808-15.
71. Arnt CR, Chiorean MV, Heldebrant MP, Gores GJ, Kaufmann SH. Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. J Biol Chem 2002; 277:44236-43. (Pubitemid 36157856)
72. Guo F, Nimmanapalli R, Paranawithana S, Wittman S, Griffin D, Bali P, et al. Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative-(BMS 247550) and Apo-2L/TRAIL-induced apoptosis. Blood 2002; 99:3419-26. (Pubitemid 34525325)
73. Kashkar H, Haefs C, Shin H, Hamilton-Dutoit SJ, Salvesen GS, Kronke M, et al. Jurgensmeier JM. XIAP-mediated caspase inhibition in Hodgkin's lymphoma-derived B cells. J Exp Med 2003; 198:341-7. (Pubitemid 36987859)
74. Deshaies RJ. SCF and Cullin/Ring H2-based ubiquitin ligases. Annu Rev Cell Dev Biol 1999; 15:435-67. (Pubitemid 32250383)
75. Sun Y, Tan M, Duan H, Swaroop M. SAG/ROC/Rbx/Hrt, a zinc RING finger gene family: Molecular cloning, biochemical properties, and biological functions. Antioxid Redox Signal 2001; 3:635-50. (Pubitemid 32785986)
76. Zheng N, Schulman BA, Song L, Miller JJ, Jeffrey PD, Wang P, et al. Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex. Nature 2002; 416:703-9. (Pubitemid 34429140)
77. Cenciarelli C, Chiaur DS, Guardavaccaro D, Parks W, Vidal M, Pagano M. Identification of a family of human F-box proteins. Curr Biol.1999; 9:1177-9. (Pubitemid 29527103)
78. Winston JT, Koepp DM, Zhu C, Elledge SJ, Harper JW. A family of mammalian F-box proteins. Curr Biol 1999; 9:1180-2.
79. Chen LC, Manjeshwar S, Lu Y, Moore D, Ljung BM, Kuo WL, et al. The human homologue for the Caenorhabditis elegans cul-4 gene is amplified and overexpressed in primary breast cancers. Cancer Res 1998; 58:3677-83. (Pubitemid 28376568)
80. Gstaiger M, Jordan R, Lim M, Catzavelos C, Mestan J, Slingerland J, et al. Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci USA 2001; 98:5043-8. (Pubitemid 32397079)
81. Yokoi S, Yasui K, Saito-Ohara F, Koshikawa K, Iizasa T, Fujisawa T, et al. A novel target gene, SKP2, within the 5p13 amplicon that is frequently detected in small cell lung cancers. Am J Pathol 2002; 161:207-16. (Pubitemid 34760786)
82. Signoretti S, Di Marcotullio L, Richardson A, Ramaswamy S, Isaac B, Rue M, et al. Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest 2002; 110:633-41. (Pubitemid 34988787)
83. Yang G, Ayala G, Marzo AD, Tian W, Frolov A, Wheeler TM, et al. Elevated Skp2 protein expression in human prostate cancer: Association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin Cancer Res 2002; 8:3419-26. (Pubitemid 35340716)
84. Hershko D, Bornstein G, Ben-Izhak O, Carrano A, Pagano M, Krausz MM, et al. Inverse relation between levels of p27(Kip1) and of its ubiquitin ligase subunit Skp2 in colorectal carcinomas. Cancer 2001; 91:1745-51. (Pubitemid 32377961)
85. Masuda TA, Inoue H, Sonoda H, Mine S, Yoshikawa Y, Nakayama K, et al. Clinical and biological significance of S-phase kinase-associated protein 2 (Skp2) gene expression in gastric carcinoma: Modulation of malignant phenotype by Skp2 overexpression, possibly via p27 proteolysis. Cancer Res 2002; 62:3819-25. (Pubitemid 34728867)
86. Kudo Y, Kitajima S, Sato S, Miyauchi M, Ogawa I, Takata T. High expression of S-phase kinase-interacting protein 2, human F-box protein, correlates with poor prognosis in oral squamous cell carcinomas. Cancer Res 2001; 61:7044-7. (Pubitemid 32946493)
87. Strohmaier H, Spruck CH, Kaiser P, Won KA, Sangfelt O, Reed SI. Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature 2001; 413:316-22. (Pubitemid 32905853)
88. Spruck CH, Strohmaier H, Sangfelt O, Muller HM, Hubalek M, Muller-Holzner E, et al. CDC4 gene mutations in endometrial cancer. Cancer Res 2002; 62:4535-9.
89. Laney JD, Hochstrasser M. Substrate targeting in the ubiquitin system. Cell 1999; 97:427-30.
90. Bhatia N, Herter JR, Slaga TJ, Fuchs SY, Spiegelman VS. Mouse homologue of HOS (mHOS) is overexpressed in skin tumors and implicated in constitutive activation of NF-kappaB. Oncogene 2002; 21:1501-9.
91. Duan H, Wang Y, Aviram M, Swaroop M, Loo JA, Bian J, et al. SAG, a novel zinc RING finger protein that protects cells from apoptosis induced by redox agents. Mol Cell Biol 1999; 19:3145-3155. (Pubitemid 29144559)
92. Huang Y, Duan H, Sun Y. Elevated expression of SAG/ROC2/Rbx2/Hrt2 in human colon carcinomas: SAG does not induce neoplastic transformation, but its antisense transfection inhibits tumor cell growth. Mol Carcinog 2001; 30:62-70. (Pubitemid 32127351)
93. Sasaki H, Yukiue H, Kobayashi Y, Moriyama S, Nakashima Y, Kaji M, et al. Expression of the sensitive to apoptosis gene, SAG, as a prognostic marker in nonsmall cell lung cancer. Int J Cancer 2001; 95:375-7. (Pubitemid 33015108)
94. Shim EH, Johnson L, Noh HL, Kim YJ, Sun H, Zeiss C, Zhang H. Expression of the F-Box Protein SKP2 Induces Hyperplasia, Dysplasia, and Low-Grade Carcinoma in the Mouse Prostate. Cancer Res 2003; 63:1583-8.
95. Sun Y. Alteration of SAG mRNA in human cancer cell lines: Requirement for the RING finger domain for apoptosis protection. Carcinogenesis 1999; 20:1899-1903. (Pubitemid 29476114)
96. Yang GY, Pang L, Ge HL, Tan M, Ye W, Liu XH, et al. Attenuation of ischemia-induced mouse brain injury by SAG, a redox- inducible antioxidant protein. J Cereb Blood Flow Metab 2001; 21:722-33. (Pubitemid 32510460)
97. Chanalaris A, Sun Y, Latchman DS, Stephanou A. SAG attenuates apoptotic cell death caused by simulated ischaemia/reoxygenation in rat cardiomyocytes. J Mol Cell Cardiol 2003; 35:257-64. (Pubitemid 36379169)
98. Duan H, Tsvetkov LM, Liu Y, Song Y, Swaroop M, Wen R, et al. Sun Y. Promotion of S-phase entry and cell growth under serum starvation by SAG/ROC2/Rbx2/Hrt2, an E3 ubiquitin ligase component: Association with inhibition of p27 accumulation. Mol Carcinog 2001; 30:37-46.
99. Wu K, Fuchs SY, Chen A, Tan P, Gomez C, Ronai Z, et al. The SCF(HOS/beta-TRCP)-ROC1 E3 ubiquitin ligase utilizes two distinct domains within CUL1 for substrate targeting and ubiquitin ligation. Mol Cell Biol 2000; 20:1382-93. (Pubitemid 30069258)
100. Furukawa M, Ohta T, Xiong Y. Activation of UBC5 ubiquitin-conjugating enzyme by the RING finger of ROC1 and assembly of active ubiquitin ligases by all cullins. J Biol Chem 2002; 277:15758-65. (Pubitemid 34967851)
101. Swaroop M, Wang Y, Miller P, Duan H, Jatkoe T, Madore S, et al. Yeast homolog of human SAG/ROC2/Rbx2/Hrt2 is essential for cell growth, but not for germination: Chip profiling implicates its role in cell cycle regulation. Oncogene 2000; 19:2855-2866.
102. Davydov IV, Safiran Y J, Oberoi P, Yang Y, Vousden K H, Woods D, et al. Inhibitors of Mdm2 ubiquitylation. Ubiquitination in Normal and Cancer Cells. 2002; AACR Special Conference, Vancouver, BC, Canada, 2002:pp40.
103. Boisclair MD, McClure C, Josiah S, Glass S, Bottomley S, Kamerkar S, et al. Development of a ubiquitin transfer assay for high throughput screening by fluorescence resonance energy transfer. J Biomol Screen 2000; 5:319-28.
104. Speedy approvals for new cancer treatments. FDA Consum 2003; 37:36.
105. Adams J. Proteasome inhibition in cancer: Development of PS-341. Semin Oncol 2001; 28:613-9. (Pubitemid 33134421)
106. Adams J. Potential for proteasome inhibition in the treatment of cancer. Drug Discov Today 2003; 8:307-15. (Pubitemid 36332222)